ReviewInflammopharmacology2025
The renin-angiotensin system (RAS) and arthritic diseases: therapeutic potential for RAS inhibitors.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Can Certain Antihypertensives Prolong the Efficacy of Hyaluronic Acid Injections in Patients with Osteoarthritis of the Knee? Post Hoc Analysis of a Prospective Observational Trial (PRESAGE).Journal of clinical medicine · 2026Article
- The joint-local renin-angiotensin system in rheumatoid arthritis and osteoarthritis: mechanistic evidence, disease-specific patterns, and translational perspectives.Rheumatology international · 2026Review
- Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The renin-angiotensin system (RAS) is a pivotal hormonal regulator of cardiovascular and renal homeostasis, recently implicated in the etiology and progression of inflammatory arthritis, including rheumatoid arthritis (RA) and osteoarthritis (OA). This review explores the dual nature of RAS, highlighting its classical axis (ACE/Ang II/AT1R), which promotes inflammation and tissue damage, and its counter-regulatory axis (ACE2/Ang-(1-7)/MasR), which exhibits anti-inflammatory and protective effects. Elevated levels of RAS components in synovial fluid of arthritis patients emphasize its role in local joint pathology. The potential of RAS inhibitors, including angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs), is discussed, demonstrating their efficacy in reducing inflammatory cytokines, oxidative stress, and immune dysregulation. Emerging research also underscores the protective effects of the counter-regulatory axis in mitigating inflammation, oxidative stress, and angiogenesis, which are crucial in arthritis progression. The review further explores innovative therapeutic strategies, such as AI-powered personalized and tailored medicine, to optimize RAS-targeted therapies for enhanced efficacy and patient-specific outcomes. This evolving field highlights the promise of integrating RAS modulation with advanced diagnostic and therapeutic technologies to revolutionize arthritis treatment, offering hope for better disease management and improved quality of life.
Indexed as
Identifiers
40796991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.